Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602258 · ClinicalTrials.gov registry record · Phase 2
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Eisai.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT06602258: Active Phase 2 study of Alzheimers Disease, sponsored by Eisai.
NCT06602258 is a Phase 2 study of Alzheimers Disease that is active but no longer recruiting, run by Eisai. The registered enrollment target is 105 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602258, a Phase 2 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eisai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lecanemab
- DRUG E2814
Study Locations (20)
Florida
- Bradenton Research Center - Bradenton
- K2 Medical Research - Clermont
- Advanced Clinical Research Network - Miami
- Renstar Medical Research - Ocala
- Progressive Medical Research - Port Orange
- Alzheimer's Research and Treatment Center-Stuart - Stuart
- Axiom Brain Health - Tampa
- Charter Research - The Villages
- Alzheimer's Research and Treatment Center - Wellington
Arizona
- Banner Sun Health Research - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Columbus Memory Center, PC - Columbus
Mississippi
- Hattiesburg Clinic - Hattiesburg
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Abington Neurological Associates LTD - Abington
Tennessee
- Neurology Clinic, P.C. - Cordova
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-08-18 |
| Phase | Phase 2 |
What the registry record for NCT06602258 still lists
NCT06602258 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06602258 names 20 study sites across 12 states, led by Florida, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06602258 about?
NCT06602258 is a clinical study titled "A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease". The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
What is the current status of trial NCT06602258?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2024-09-30. Estimated completion is 2027-08-18.
What conditions does trial NCT06602258 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06602258?
The interventions under investigation include: Placebo (DRUG), Lecanemab (DRUG), E2814 (DRUG).
Who is sponsoring clinical trial NCT06602258?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06602258 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Georgia, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06602258's enrollment target sits among peer trials
105 74th of 147 higher than 74 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI